MUMBAI: Drug major AstraZeneca is stepping on the gas in the fight against the Covid-19 virus, with plans to launch a next-generation jab to address the emerging strains, a cocktail of the two. monoclonal antibodies for prevention-to-treatment, and a booster shot of its current vaccine.
NS covid treatment Including the vaccine is expected to be launched in India next year, and the serum may be manufactured at the institute, sources told TOI. As these treatments are under development or under testing, the final agreement is yet to be signed.
“AstraZeneca is working with governments around the world to make AZD7442 (cocktail of monoclonal antibodies) accessible to high-risk populations as another valuable option in the fight to end COVID, whether it is effective and well tolerated. Must be proved tolerable. Additionally, the new COVID-19 variant vaccine AZD2816 is under trial and once preliminary data are available, will be submitted to regulators for evaluation as a next generation booster vaccine and through an accelerated regulatory route, Gagandeep Singh, MD, AstraZeneca India told TOI.
The next generation vaccine is undergoing trials in the UK and Brazil. The company has accelerated efforts to advance the development of an antibody cocktail – a long-acting antibody combination – for possible prevention and treatment of COVID-19.
NS covid treatment Including the vaccine is expected to be launched in India next year, and the serum may be manufactured at the institute, sources told TOI. As these treatments are under development or under testing, the final agreement is yet to be signed.
“AstraZeneca is working with governments around the world to make AZD7442 (cocktail of monoclonal antibodies) accessible to high-risk populations as another valuable option in the fight to end COVID, whether it is effective and well tolerated. Must be proved tolerable. Additionally, the new COVID-19 variant vaccine AZD2816 is under trial and once preliminary data are available, will be submitted to regulators for evaluation as a next generation booster vaccine and through an accelerated regulatory route, Gagandeep Singh, MD, AstraZeneca India told TOI.
The next generation vaccine is undergoing trials in the UK and Brazil. The company has accelerated efforts to advance the development of an antibody cocktail – a long-acting antibody combination – for possible prevention and treatment of COVID-19.
.